GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) Valuation
Historical valuation analysis based on 1278 data points (2021-09-10 to 2026-10-16)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines...
GSK plc American Depositary Shares (Each representing two Ordinary Shares) trades near its historical valuation range, with most metrics close to their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) Valuation & P/E History
GSK plc American Depositary Shares (Each representing two Ordinary Shares) (GSK) is a US-listed stock operating in the Healthcare sector, specifically the Drug Manufacturers - General industry currently trading at $49.51 with a market capitalization of $99.2 billion. This page provides historical valuation analysis for GSK based on 1278 data points covering 2021-09-10 to 2026-10-16...
GSK Valuation Metrics & Historical Range
The valuation table above shows GSK plc American Depositary Shares (Each representing two Ordinary Shares)'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether GSK is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests GSK is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for GSK plc American Depositary Shares (Each representing two Ordinary Shares).
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is GSK Overvalued or Undervalued?
GSK plc American Depositary Shares (Each representing two Ordinary Shares) trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 50 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive GSK is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full GSK analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.GSK trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.